Copper Peptides (GHK-Cu): What They Do for Skin and Hair

Copper Peptides (GHK-Cu), Defined

GHK-Cu (glycyl-L-histidyl-L-lysine:copper) is a naturally occurring tripeptide-copper complex first identified in human plasma in 1973. Plasma levels decline with age, a pattern first described in Pickart's early work on the tripeptide. Today it is sold as a cosmetic ingredient in topical serums and creams. It is not FDA-approved as a drug.

The complex is built from three amino acids. Glycine, histidine, and lysine. Bound to a single copper ion. That bound form is the bioactive unit. Topical products typically contain 1–2% peptide concentration, though formulation stability varies considerably across manufacturers. A comprehensive 2018 review remains the foundational reference for GHK-Cu's mechanism and regenerative actions.

GHK-Cu is produced synthetically or via biotech methods; product quality depends heavily on formulation stability. It is commonly confused with two distinct things: copper bisglycinate, which is a mineral supplement with a completely different mechanism, and injectable GHK-Cu peptide therapy, which is a clinician-guided category with different evidence and risk considerations. These are not interchangeable.

How GHK-Cu Works on Skin and Scalp

The central question is whether GHK-Cu acts locally at the skin and follicle, systemically through circulation, or both. Topical evidence is the strongest layer by far. Systemic applications remain more speculative.

Local action on skin and follicle

At the tissue level, GHK-Cu is thought to activate genes involved in collagen synthesis and extracellular matrix remodeling. A 2023 study observed collagen IV upregulation in fibroblasts and ex-vivo skin when GHK-Cu was combined with hyaluronic acid. The complex has also been observed to modulate matrix metalloproteinase (MMP) activity. Enzymes that break down collagen, and to support angiogenesis. A 2017 study demonstrated accelerated wound healing via cell proliferation and angiogenesis in a scald-wound mouse model using GHK-Cu liposomes. Notably, a 2012 study showed that GHK without copper still has skin-stem-cell activity, suggesting the tripeptide itself carries meaningful biological signaling independent of the copper ion.

Whether it reaches the bloodstream, and what that means

At cosmetic concentrations applied topically, GHK-Cu acts almost entirely locally. Meaningful systemic absorption through intact skin is minimal. Claims that topical GHK-Cu delivers systemic anti-inflammatory or immune-support effects draw on plasma physiology that does not translate to a serum applied to the face. Injectable GHK-Cu is a separate category entirely. It does achieve systemic exposure, but clinical-trial evidence at that level is thin, and use without clinician guidance is not appropriate. Injectable GHK-Cu is a separate regulatory category. Injectable GHK-Cu is not FDA-approved as a drug. As of May 2026, FDA lists non-injectable GHK-Cu as Category 1 under evaluation for 503A compounding, while injectable GHK-Cu remains a separate concern because FDA has identified limited human safety data and potential immunogenicity risks for compounded injectable products. Superpower does not provide, prescribe, or facilitate access to injectable GHK-Cu through this content. To be explicit: copper bisglycinate (a mineral supplement) and GHK-Cu (a signaling tripeptide-copper complex) are different compounds with different mechanisms and applications. Do not conflate them.

Grading the GHK-Cu Claims

Evidence quality across these claims ranges from anecdotal to strong.

Skin collagen synthesis and anti-wrinkle support: Moderate

Research suggests topical GHK-Cu may support collagen synthesis in skin. A 2018 review synthesizes decades of mechanistic and small-trial data on collagen-related gene activation. A 2023 study documented collagen IV upregulation at the fibroblast and ex-vivo skin level, providing a mechanistic anchor. A 2025 review evaluated GHK-Cu as a topical anti-wrinkle peptide, noting both its promise and formulation challenges. A 2006 controlled clinical trial examined topical copper tripeptide complex on CO2 laser-resurfaced skin and found no objective improvement in wrinkles or skin quality versus control, though patient satisfaction was higher with GHK-Cu. The evidence base is real but limited by small trial sizes, controlled aesthetic settings, and formulation variability. "May support" is the accurate framing. Not "reverses skin aging."

Wound healing: Limited

A 2017 study showed GHK-Cu liposomes accelerated scald wound healing in mice through cell proliferation and angiogenesis pathways. A 2007 preclinical study explored biotinylated GHK in collagen matrices for diabetic wound healing. The molecular biology is well-developed and mechanistically coherent. Clinical translation in healthy human populations, however, remains limited. This is a promising area. Not a proven one.

Topical hair growth: Animal-only

Hair-growth evidence for GHK-Cu does not yet include large human clinical trials. A 2007 study examined a related tripeptide-copper complex (AHK-Cu) on isolated human hair follicles in vitro. Not a clinical trial. A 1991 study demonstrated hair follicle-stimulating properties of peptide-copper complexes in C3H mice. A classic preclinical reference, now over three decades old. Research suggests possible follicle-level activity. "Regenerates hair" is not a claim the current evidence supports.

Anti-inflammatory and antioxidant skin protection: Pre-clinical

A 2012 review described GHK-Cu's role in preventing oxidative skin damage and its implications for degenerative aging conditions. A 2014 review explored GHK's broader gene-expression effects, including pathways relevant to inflammation and cellular repair. The mechanistic picture is well-developed at the molecular level. Direct clinical evidence in humans for anti-inflammatory skin protection specifically remains limited.

Applying Copper Peptides on Skin and Scalp

For those whose evidence review lands in the "worth trying" column, the application approach should match the mechanisms the research actually supports.

Where to apply

Topical GHK-Cu serums and creams are applied to the face and scalp. The sites where the collagen-synthesis and follicle-level evidence is concentrated. Before broader use, patch-test on the inner forearm first. High-percentage vitamin C, retinoids, and AHAs should not be applied at the same time of day as GHK-Cu. Acidic conditions destabilize the peptide-copper complex, reducing its activity. Separating applications by time of day. GHK-Cu in the morning, retinoid in the evening, for example. Preserves both.

How often, and patch-test first

Most topical GHK-Cu products are labeled for once or twice daily use; the published literature does not specify a single studied frequency the way prescription trials do. A patch test means applying a small amount to the inner forearm and waiting 24–48 hours before broader application. Patch tests reduce but do not eliminate the risk of delayed contact dermatitis. For scalp applications, monitor the hairline area for irritation, which can appear separately from the scalp itself.

Who Topical GHK-Cu Suits, and Who Should Skip

Topical GHK-Cu may suit adults seeking anti-aging or scalp-support options as part of a broader skincare routine. It is reasonable for people whose current routines do not involve same-time vitamin C, retinoid, or AHA use, or who are willing to separate applications by time of day. "May suit" is the operative phrase; individual skin response varies.

• Use high-percentage vitamin C, retinoids, or AHAs at the same time of day (acidic conditions destabilize the peptide complex. Separate by time of day instead).
• Have known copper sensitivity or diagnosed Wilson's disease (systemic copper concerns).
• Are using injectable GHK-Cu or considering it without clinician guidance (peptide therapy is a different category from cosmetic topical use).
• Have undiagnosed scalp or skin conditions (active dermatitis, suspected skin cancer). Clinical evaluation first.

Pregnant or breastfeeding individuals, those on prescription topicals for an existing skin condition, immunocompromised individuals, and anyone with a relevant chronic dermatologic condition should speak with a clinician before starting. If any of this applies, the right next step is a clinician. Not a different wellness protocol.

GHK-Cu: Side Effects, FDA Status, and the Copper-Mineral Distinction

FDA status. Topical GHK-Cu is regulated as a cosmetic ingredient, not as a drug. Therapeutic claims. Anti-aging, wound healing. Are not FDA-evaluated for cosmetic-grade GHK-Cu products. A 2020 review provides useful context on the regulatory landscape for approved peptide therapeutics, a category that topical GHK-Cu cosmetics do not currently enter.

Common side effects. Topical GHK-Cu has been associated with possible local irritation and, in rare cases, contact sensitization. Case reports describe transient mild flushing at the application site in a minority of users. Very high concentrations have been associated with transient skin color changes at the application site.

Drug interactions and the copper-mineral distinction. Copper bisglycinate (a mineral supplement) and GHK-Cu (a signaling tripeptide-copper complex) are different compounds with different mechanisms and applications. Do not conflate them. Same-time application with vitamin C, retinoids, or AHAs reduces peptide-complex stability and should be avoided. Injectable GHK-Cu carries different safety considerations from topical cosmetic use and requires clinician oversight. It is not an extension of a topical skincare routine.

Pregnancy and breastfeeding. Topical GHK-Cu safety in pregnancy and breastfeeding has not been extensively studied. Given minimal systemic absorption from topical cosmetic use, the risk is generally considered low, but specific pregnancy data is limited. Clinician sign-off is appropriate before introducing any new topical product during pregnancy or breastfeeding.

The Markers That Inform GHK-Cu Use

Topical GHK-Cu efficacy is assessed primarily at the skin. Through clinical aesthetic outcomes and photographic tracking. Not through bloodwork. The biomarkers below inform safety and category-fit, particularly for anyone considering systemic peptide therapy alongside topical use.

• Copper (serum): Baseline systemic copper status is relevant to the GHK-Cu-vs-copper-bisglycinate distinction and helps flag possible copper-handling disorders (e.g., Wilson's disease) or copper deficiency for clinical evaluation before any peptide therapy is considered.
• Ceruloplasmin: The primary copper-binding protein in plasma. Paired with serum copper, ceruloplasmin helps assess copper metabolism and flag possible copper-handling disorders for clinical evaluation before systemic copper exposure.
• Zinc:copper ratio: Zinc and copper compete for intestinal absorption. The ratio informs whether someone considering systemic copper exposure has an appropriate mineral balance as a starting point.

When Topical GHK-Cu Isn't the Answer

Progressive hair loss, skin changes that suggest disease, chronic non-healing wounds, or suspected hormone-driven dermatologic issues are clinical presentations. Not OTC purchase decisions. A dermatology workup for hair loss rules out androgenetic alopecia patterns, thyroid drivers, and iron deficiency before any topical intervention makes sense. Chronic skin changes and non-healing wounds belong in primary care or dermatology, not a skincare routine.

Measuring before applying anything new, then measuring again, is the foundation of Superpower's approach to preventive health.

Alternatives Worth Considering

Topical retinoids, niacinamide, and vitamin C serums each address collagen synthesis and skin aging through distinct mechanisms and carry different evidence profiles than GHK-Cu.

• Topical GHK-Cu (this article's subject). The evidence for topical GHK-Cu in skin collagen synthesis and anti-wrinkle is Moderate; cost-of-entry varies widely ($30–$150 for a serum). Best suited for readers seeking topical anti-aging support compatible with their existing routine.
• Topical retinoids (Rx tretinoin or OTC retinol). Tretinoin sits at Strong evidence for anti-aging and photoaging outcomes with decades of clinical data; cost is typically $30–$80/month at Rx pricing. Best suited for readers with photoaging concerns who can tolerate retinoid acclimation.
• Topical minoxidil (for hair). Minoxidil 2–5% has Strong evidence for hair regrowth in androgenetic alopecia; cost is typically $20–$50/month OTC. Best suited for readers with diagnosed androgenetic alopecia rather than general hair-density goals.
• Copper bisglycinate (mineral supplement. Different category). For systemic copper status, copper bisglycinate addresses mineral repletion. Not peptide signaling. It is not a substitute for or equivalent to GHK-Cu. Best suited for clinically documented low copper status.

The strongest clinical-trial evidence in this space sits with retinoids for photoaging and minoxidil for androgenetic alopecia. GHK-Cu holds Moderate evidence for skin collagen support and Animal-only evidence for hair. The copper bisglycinate comparison exists to draw a clear line between mineral supplementation and peptide therapy. Two distinct categories that address copper biology through entirely different mechanisms.